MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 30, 2008
Trial Information
Current as of August 21, 2025
Completed
Keywords
ClinConnect Summary
We will measure plasmatic sFlt-1 level between 25 and 28 weeks of gestation and flow velocity of uterine arteries by Doppler (22 - 26 weeks of gestation) in primipara. Patients will be stratified according to the results of the uterine artery Doppler measurement, and then randomized in two groups A and B. In group A, sFlt-1 concentration will be communicated to the obstetrician (+ or -): the threshold of abnormally high plasmatic concentration of sFlt-1 is 957 ng/mL. In patients with a high plasmatic concentration of sFlt-1 (+), the pregnancy will be closely monitored including repeated cli...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant womenAge ≥ 18 years
- • Followed in our center before the 28th week of gestation
- • Under social security coverage
- • Signed informed consent
- Exclusion Criteria:
- • Age \< 18 years
- • Followed in our center after the 28th week of gestation
- • No social security coverage
- • Refusal to be included
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Nadia BERKANE, MD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials